Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer

Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer

Abstract Background Better predictors of patients with stage II/III gastric cancer (GC) most likely to benefit from adjuvant chemotherapy are urgently needed. This study aimed to assess the ability of CDX2 and mucin markers to predict prognosis and fluorouracil‐based adjuvant chemotherapy benefits....

Full description

Bibliographic Details
Main Authors: Xianchun Gao, Weili Han, Ling Chen, Hongwei Li, Fenli Zhou, Bin Bai, Junya Yan, Yong Guo, Kun Liu, Wenjiao Li, Renlong Li, Qiangqiang Yuan, Jiehao Zhang, Yuanyuan Lu, Xiaodi Zhao, Gang Ji, Mengbin Li, Qingchuan Zhao, Kaichun Wu, Zengshan Li, Yongzhan Nie
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
adjuvant chemotherapy
CDX2
gastric cancer
immunohistochemistry
mucin
Online Access:https://doi.org/10.1002/cam4.6379

Internet

https://doi.org/10.1002/cam4.6379

Similar Items